AGÕæÈ˹ٷ½

Celularity Inc. (symbol: CELUW) filed a new Form D reporting a completed Rule 506(b) private placement. The company sold $1.035 million of equity, warrants and the underlying securities to 14 investors, with the first sale on 22 Jul 2025. The entire authorized amount has been placed, leaving $0 remaining; the offering will not last beyond one year and is unrelated to any merger or acquisition. No broker-dealers were engaged, so no sales commissions or finder’s fees were paid. The minimum investment was listed as $0, and the company states that none of the proceeds will be paid to executive officers, directors or promoters named in the filing. Celularity, incorporated in Delaware and operating from Florham Park, NJ, classified itself under the Biotechnology industry group but declined to disclose its revenue range.

NCSM’s Q2-25 10-Q shows a clear YoY turnaround. Revenue rose 23% to $36.5 mm, driven by a 46% jump in product sales that offset an 19% decline in service revenue. Consolidated gross profit improved $2.5 mm and the operating loss narrowed to $2.0 mm from $4.2 mm. A $1.0 mm deferred-tax benefit plus FX gains lifted net income attributable to NCS to $0.9 mm ($0.34 diluted EPS) versus a $3.1 mm loss (-$1.21) last year.

For the six months, revenue climbed 18% to $86.5 mm and net income swung to $5.0 mm ($1.84 diluted EPS). Canada contributed 49% of Q2 sales, the U.S. 37%, and other markets 14%.

Balance sheet. Cash remained healthy at $25.4 mm; NCS drew no amounts on its $35 mm ABL facility. Total debt consists solely of $7.7 mm of finance leases. Equity increased to $124.0 mm.

Cash flow. H1 operating cash inflow fell to $1.9 mm from $4.1 mm on higher working-capital needs; capex was modest at $0.7 mm.

Strategic update. On 31-Jul-25 NCS closed the $5.9 mm cash acquisition of Reservoir Metrics to expand tracer diagnostics, with an earn-out of up to $1.3 mm.

Risks & Outlook. Management cites stable Canadian activity, softer U.S. completions, potential international growth, and cost headwinds from steel/chemical tariffs. Ongoing Canadian patent appeals and U.S. litigation could affect future results but no gain/loss has been booked.

Amneal Pharmaceuticals (AMRX) filed an 8-K disclosing a major refinancing package. On 24 Jul 2025 the company priced $600 million of 6.875% senior secured notes due 2032 at par in a Rule 144A/Reg S private placement. The note size was reduced from the previously announced $750 million.

Concurrently, subsidiary Amneal Pharmaceuticals LLC plans to enter a new $2.1 billion, seven-year term loan B facility, upsized by $300 million from prior guidance. Together, proceeds from the notes and the new term B loans will be used to refinance existing term B loans and fully repay amounts outstanding under the ABL facility, along with related fees and expenses. The note offering is not contingent upon closing of the new term loan; both transactions are expected to close 1 Aug 2025, subject to customary conditions.

The securities will not be registered under the Securities Act and are being offered only to qualified institutional buyers (Rule 144A) and non-U.S. persons (Reg S).

Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K announcing a two-part debt refinancing initiative. Its operating subsidiary is marketing $1.8 billion of new seven-year term loan B debt and has launched a private offering of $750 million senior secured notes due 2032. Net proceeds are earmarked to (i) refinance the company’s existing term B loans in full, (ii) repay a portion of borrowings under the ABL facility, and (iii) cover related fees and expenses.

The notes will be issued under Rule 144A/Reg S and will not be registered with the SEC. Completion, size and terms of both transactions remain subject to market conditions; the notes offering is not contingent on closing of the new term loan facility. No financial results or forward guidance were provided.

Key takeaways for investors:

• Potentially extends weighted-average debt maturity to 2032.
• Transaction could restructure up to $2.55 billion of the capital stack.
• Execution risk exists because neither transaction is assured.

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) filed an 8-K dated 21-Jul-2025 disclosing two principal items:

• Item 2.02 â€� Preliminary Q2 2025 results: The company issued a press release (Ex. 99.1) with unaudited second-quarter figures. Numerical details are not included in the filing; the release is incorporated by reference but treated as “furnished,â€� not “filed,â€� under the Exchange Act.
• Item 5.02 â€� Board change: Ownership of Class A shares held by Amneal Group investors fell below a majority threshold, reducing their Board designee rights from six to five under the Stockholders Agreement. Consequently, Amneal Group designee Emily Peterson Alva resigned from the Board and Audit Committee effective 16-Jul-2025. The company states the resignation involved no disagreement with management, the Board, or company policies.

No other material transactions, financial statements, or guidance updates are provided in this report. The filing contains customary Regulation FD and exhibit listings.